title: Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge.
abstract: Anthrax has long been considered the most probable bioweapon-induced disease. The protective antigen (PA) of Bacillus anthracis plays a crucial role in the pathogenesis of anthrax. In the current study, we evaluated the efficiency of a genetic vaccination with the fourth domain (D4) of PA, which is responsible for initial binding of the anthrax toxin to the cellular receptor. The eukaryotic expression vector was designed with the immunoglobulin M (IgM) signal sequence encoding for PA-D4, which contains codon-optimized genes. The expression and secretion of recombinant protein was confirmed in vitro in 293T cells transfected with plasmid and detected by western blotting, confocal microscopy, and enzyme-linked immunosorbent assay (ELISA). The results revealed that PA-D4 protein can be efficiently expressed and secreted at high levels into the culture medium. When plasmid DNA was given intramuscularly to mice, a significant PA-D4-specific antibody response was induced. Importantly, high titers of antibodies were maintained for nearly 1 year. Furthermore, incorporation of the SV40 enhancer in the plasmid DNA resulted in approximately a 15-fold increase in serum antibody levels in comparison with the plasmid without enhancer. The antibodies produced were predominantly the immunoglobulin G2 (IgG2) type, indicating the predominance of the Th1 response. In addition, splenocytes collected from immunized mice produced PA-D4-specific interferon gamma (IFN-γ). The biodistribution study showed that plasmid DNA was detected in most organs and it rapidly cleared from the injection site. Finally, DNA vaccination with electroporation induced a significant increase in immunogenicity and successfully protected the mice against anthrax spore challenge. Our approach to enhancing the immune response contributes to the development of DNA vaccines against anthrax and other biothreats.
authors.affiliation: Department of Life Science, Sogang University, Seoul, Republic of Korea.
authors.forename: Na Young
authors.initials: NY
authors.lastname: Kim
authors.affiliation: Department of Life Science, Sogang University, Seoul, Republic of Korea.
authors.forename: Dong Suk
authors.initials: DS
authors.lastname: Chang
authors.affiliation: Department of Life Science, Sogang University, Seoul, Republic of Korea.
authors.forename: Yeonsu
authors.initials: Y
authors.lastname: Kim
authors.affiliation: Agency for Defense Development, Daejeon, Republic of Korea.
authors.forename: Chang Hwan
authors.initials: CH
authors.lastname: Kim
authors.affiliation: Agency for Defense Development, Daejeon, Republic of Korea.
authors.forename: Gyeung Haeng
authors.initials: GH
authors.lastname: Hur
authors.affiliation: Department of Life Science, Sogang University, Seoul, Republic of Korea.
authors.forename: Jai Myung
authors.initials: JM
authors.lastname: Yang
authors.affiliation: Department of Life Science, Sogang University, Seoul, Republic of Korea.
authors.forename: Sungho
authors.initials: S
authors.lastname: Shin
mesh_terms: D000818:Animals; D022122:Anthrax Vaccines / Q000276:immunology*; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001408:Bacillus anthracis / Q000276:immunology* / Q000502:physiology; D006168:Guinea Pigs; D051379:Mice; D013171:Spores, Bacterial / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D022122:Anthrax Vaccines; D000907:Antibodies, Bacterial; D019444:Vaccines, DNA